Histoplasmosis Treatment Market Share

North American Market Forecasts

The histoplasmosis treatment market in the North America region is anticipated to gain the largest revenue share of 33% throughout the projected period. The United States is considered to be the dominant country in terms of disease growth rate and is set to be the country to expand the histoplasmosis treatment market the most. This is due to the increasing number of patients with malignant diseases and immunodeficiency.  According to the CDC, in North America histoplasmosis is the most common disease in HIV/AIDS patients, of which 4,444 and 30% of patients die due to their immunocompromised state. Additionally, an increasing research and development and technological advancements in the region are some of the driving forces for the histoplasmosis treatment market.  

European Market Statistics

The histoplasmosis treatment market in the Europe region is anticipated to hold substantial growth in the time period between 2024-2036. Increasing focus on medical facilities and increasing population aged 65 and above are expected to drive market growth. Furthermore, the demand for the histoplasmosis treatment market is increasing due to the rise in chronic diseases that weaken the human immunity of people in the region. Furthermore, the European Union also offers support for the advancement of healthcare infrastructure and improving the healthcare industry in Europe. They consecutively offer funds for the research and development of novel therapies in order to offer enhanced histoplasmosis treatment to patients in this region.